What it's for (Indications)
- This combination medication, containing diflucortolone and isoconazole, is primarily indicated for the initial treatment of various inflammatory skin conditions where a fungal or mixed fungal/bacterial infection is present or strongly suspected.
- Specifically, it is prescribed for dermatoses such as tinea infections (e.
- g.
- , tinea corporis, tinea cruris, tinea pedis), cutaneous candidiasis, and other superficial fungal infections that are accompanied by significant inflammatory symptoms like erythema, pruritus, and scaling.
- The presence of the corticosteroid diflucortolone rapidly alleviates these inflammatory manifestations, while the antifungal agent isoconazole targets and eradicates the underlying fungal pathogen.
- It is particularly useful in cases where the inflammation is pronounced and requires prompt relief, making it a valuable option for the acute phase of these dermatomycoses.
- Furthermore, its broad-spectrum antifungal activity, coupled with some antibacterial efficacy of isoconazole against susceptible Gram-positive bacteria, makes it suitable for mixed infections where both fungal and bacterial components contribute to the dermatological condition.
- Use should always be under the guidance of a healthcare professional following a confirmed diagnosis or strong clinical suspicion.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Travocort Cream, containing diflucortolone valerate and isoconazole nitrate, is intended for external use only. A thin layer of the cream should be applied to the affected skin area(s) usually once or twice daily. The precise frequency and duration of treatment must be determined by a healthcare professional based on the severity and nature of the condition, as well as the patient's response to therapy. Typically, the treatment course should be limited to a maximum of two to four weeks, especially due to the potent corticosteroid component. For conditions where the inflammatory symptoms subside rapidly, it is advisable to switch to an antifungal-only preparation to complete the fungal eradication phase and minimize corticosteroid exposure. In pediatric patients, the use of diflucortolone-containing preparations should be approached with extreme caution, and the duration of treatment should be as short as possible, avoiding application to large surface areas or under occlusive dressings, due to the increased risk of systemic absorption and potential adrenal suppression. Patients should be instructed to gently rub the cream into the skin until it is absorbed and to wash their hands thoroughly after application. Discontinuation should be gradual if prolonged use has occurred, to prevent rebound phenomena. |
Safety & Warnings
Common Side Effects
- As with any topical medication containing corticosteroids and antifungals, diflucortolone + isoconazole cream may cause various side effects, although generally well-tolerated when used as directed for short durations.
- Common local side effects attributable to the corticosteroid component include skin atrophy (thinning), striae (stretch marks), telangiectasias (spider veins), hypopigmentation, folliculitis, hypertrichosis (excessive hair growth), and acneiform eruptions, especially with prolonged use, on facial skin, or in intertriginous areas.
- Systemic effects, such as HPA axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria, are rare but can occur, particularly with extensive application, prolonged use, under occlusive dressings, or in children.
- The isoconazole component may cause local irritation, burning, itching, erythema, or dryness at the application site.
- Allergic contact dermatitis to either active ingredient or excipients is also possible, presenting as worsening redness, itching, or swelling.
- If any of these local reactions become severe or persistent, or if signs of systemic absorption appear, treatment should be discontinued, and a physician consulted.
- Other potential, albeit less common, side effects include perioral dermatitis and rebound phenomena upon abrupt discontinuation after prolonged use.
Serious Warnings
- Black Box Warning: None
- This combination preparation is contraindicated in patients with known hypersensitivity to diflucortolone, isoconazole, or any other excipients.
- It should not be used in the presence of viral infections (e.
- g.
- , herpes simplex, varicella, shingles) in the treatment area, or skin conditions such as rosacea, perioral dermatitis, acne vulgaris, and syphilis or tuberculosis lesions in the area to be treated, as corticosteroids can exacerbate these conditions.
- Application near the eyes should be strictly avoided due to the risk of glaucoma or cataracts with prolonged use, and to prevent irritation of ocular mucous membranes.
- Prolonged use on the face, in skin folds (intertriginous areas), or under occlusive dressings should be avoided as it increases the risk of local skin atrophy, systemic absorption, and HPA axis suppression.
- Caution is advised when treating large body surface areas, particularly in infants and young children, due to their higher skin surface area to body weight ratio, which increases systemic absorption potential.
- If irritation, sensitization, or superinfection with non-susceptible organisms occurs, treatment should be discontinued, and appropriate therapy initiated.
- Pregnant or breastfeeding women should use this medication only if the potential benefit justifies the potential risk to the fetus or infant, and under strict medical supervision, avoiding extensive application.
- Abrupt cessation after prolonged use may lead to a rebound phenomenon.
How it Works (Mechanism of Action)
The therapeutic efficacy of Travocort Cream stems from the synergistic actions of its two active components: diflucortolone valerate and isoconazole nitrate. Diflucortolone valerate is a potent synthetic fluorinated corticosteroid that exerts anti-inflammatory, anti-allergic, and antipruritic effects. It functions by diffusing across cell membranes and binding to specific glucocorticoid receptors within the cytoplasm. This complex then translocates into the nucleus, where it modulates gene expression, leading to the synthesis of proteins that inhibit the release of inflammatory mediators such as prostaglandins and leukotrienes (via inhibition of phospholipase A2). It also reduces the migration of inflammatory cells to the site of inflammation and induces vasoconstriction, thereby decreasing erythema and edema. Isoconazole nitrate is a broad-spectrum imidazole derivative antifungal agent. Its primary mechanism of action involves the inhibition of ergosterol synthesis, a critical sterol component of the fungal cell membrane. By interfering with 14-alpha demethylase, an enzyme crucial for ergosterol production, isoconazole causes structural and functional damage to the fungal cell membrane, leading to increased permeability, leakage of essential intracellular components, and ultimately fungal cell death. Isoconazole exhibits efficacy against dermatophytes, yeasts, molds, and also possesses some antibacterial activity against Gram-positive bacteria, thus addressing both fungal and potential bacterial co-infections.
Commercial Brands (Alternatives)
No other brands found for this formula.